Teclistamab

• Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infe… Pending
  2024-518420-80-00 Phase III 12 countries Takeda Development Center Americas Inc.
• TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of ly… Pending
  2025-521827-61-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 Phase III 7 countries Janssen Cilag International
• Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting
  2024-520433-76-00 Phase II 4 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment Recruiting
  2025-524022-18-00 Phase II 1 country Vaestra Goetalandsregionen
• A Trial of a novel agent in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis Recruiting
  2024-519191-90-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b… Recruiting
  2024-519498-20-00 Phase I/II 1 country Cellcentric Limited
• A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting
  2023-505221-14-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I… Recruiting
  2024-514101-65-00 Phase II 1 country Centre Hospitalier Universitaire De Lille
• A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants wit… Recruiting
  2024-517382-17-00 Phase II 1 country Universitaetsklinikum Heidelberg AöR
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting
  2023-503442-30-00 Phase III 14 countries Janssen - Cilag International
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia… Recruiting
  2023-510384-36-00 Phase III 13 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended
  2023-508310-41-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f… Ended
  2023-508212-38-00 Phase II 3 countries North Estonia Medical Centre Foundation
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended
  2022-502446-27-00 Phase III 13 countries Janssen - Cilag International
• An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab… Ended
  2024-514016-26-00 Phase II 1 country Fundacion Pethema
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended
  2023-503444-13-00 Phase III 13 countries Janssen - Cilag International
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended
  2023-503441-55-00 Phase II 10 countries Janssen - Cilag International
• A Phase 1b/2 Study of the Combination of Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Ended
  2023-503439-16-00 Phase I/II 1 country Janssen - Cilag International
• An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Ended
  2023-503438-40-00 Phase I (FiH) 7 countries Janssen - Cilag International

Showing 1–20 of 20 trials